<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C67373B7-D390-4D49-BD31-1280BA65D1F5"><gtr:id>C67373B7-D390-4D49-BD31-1280BA65D1F5</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Nutt</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/BEDA41E9-DB2B-47F2-88D5-BAB4A38D2757"><gtr:id>BEDA41E9-DB2B-47F2-88D5-BAB4A38D2757</gtr:id><gtr:firstName>Helen</gtr:firstName><gtr:otherNames>Valerie</gtr:otherNames><gtr:surname>Curran</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FJ00460X%2F1"><gtr:id>324E8425-4D37-4412-A4F7-8B7774364B82</gtr:id><gtr:title>Psilocybin as a treatment for major depression</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J00460X/1</gtr:grantReference><gtr:abstractText>The aim of this project is to test the efficacy of psilocybin as a treatment for major depression. Psilocybin is a naturally occurring compound that is found in some species of mushroom. It is structurally similar to the brain neurotransmitter serotonin - which is implicated in mood (low brain serotonin levels are associated with low mood). Psilocybin has been used for centuries in spiritual healing contexts, and more recently in psychotherapy. Modern research has shown that single exposures to psilocybin can improve psychological well-being for over 1 year and decrease symptoms of depression for up to 6 months, without any adverse events. Using functional brain imaging (fMRI) and intravenous psilocybin, we recently found brain changes that can explain these positive mood effects of psilocybin. Here we propose a well powered, placebo-controlled design to study the efficacy of psilocybin as a treatment for major depression. We will recruit 44 patients with major depression that will be randomly allocated to either a placebo group or a psilocybin group. Neither the patients, nor the research staff will know which patients are in which group ('double-blind'). Psilocybin may be particularly beneficial for patients that struggle to adhere to chronic treatment schedules, as it is potentially effective after just one exposure. It may also be particularly beneficial for patients that hold rigidly pessimistic attitudes, since psychological and neurobiological data suggest that it targets brain mechanisms involved in habitual negative thinking.</gtr:abstractText><gtr:technicalSummary>This will be a double-blind, randomised, placebo-controlled, between subjects study involving up to 44 patients (22 per group) with major depression of moderate to severe degree (scores of 14+ on the Hamilton Depression Rating scale). The main objective is to test the efficacy of psilocybin infusion as a treatment for major depression. All patients will be at least 21 years of age with decent physical health and at least one failed treatment with an antidepressant medication within the last 4 months. All patients will be medication free for at least 7 days prior to screening. Patients will be recruited via referrals and advertisement. The study will be adopted on to the Medical Health Research Network. Patients will be screened for suitability. Exclusion criteria will include: epilepsy, cardiovascular abnormalities, history of drug or alcohol dependence, history of psychosis, psychotic symptoms, bipolar disorder, or high schizotypy, and a history of suicide attempts or planning. The study duration from screening to the final formal follow-up will be 4 weeks. Upon enrolment, patients will be randomly allocated to 1 of 2 treatment groups: placebo (2 IV infusions of saline, 7 days apart) or psilocybin (2 IV infusions of psilocybin - a low dose (0.9mg) and then a high dose (1.8mg), 7 days apart). After screening, there will be a run in period of 7 days, followed by the first treatment session at day 7, a second treatment session at day 14 and a final follow-up at day 28 after which the study will end. The primary outcome will be change in BDI scores from baseline to week 4. We predict that patients in the psilocybin group will have significantly greater decreases in BDI scores than patients in the placebo group. Psilocybin will be given by IV infusion. Given IV, the acute subjective effects of psilocybin are short-lived and well-tolerated, lasting for approximately 40 minutes.</gtr:technicalSummary><gtr:potentialImpactText>Patients with depression will be the biggest beneficiaries of this research, both directly in those that are treated in the study, and later on in those that may receive the treatment if it is eventually licensed. Carers will also benefit, particularly if psilocybin is found to be effective after one or two exposures; a safe and effective single exposure therapy would have considerable value in terms of treatment efficiency and resources saved. Psilocybin may become seen as an attractive alternative to other single exposure therapies - such as electroconvulsive therapy, or perhaps, ketamine infusion. Longer-term, we might see psilocybin developed as an adjunct to cognitive behavioural therapy (CBT) and/or interpersonal psychotherapy. 
In the commercial sector, if psilocybin is shown to be safer and more effective than competing treatments, pharmaceutical companies may become interested in its development. Consistent with the aims of the multidisciplinary association of psychedelic studies (MAPS) to develop MDMA (ecstasy) as a treatment for Post Traumatic Stress Disorder, an ultimate scenario for psilocybin as a treatment for depression may be that it is offered in specialised clinics - where an appropriately high level of care can be given to patients, e.g. with careful screening, preparation and aftercare. 
In terms of lost productivity, the cost of depression for government and industry is presently immense and set to increase. Thus, if psilocybin is shown to be safe and effective in depression, increasing patients' optimism and well-being, then this would have broad positive consequences e.g. for economic performance. It is relevant to note here that certain luminaries in science and technology (e.g. Steve Jobs - Apple and Kary Mullis - PCR) have, in open press, attributed their achievements, in no small part, to insights gained on psychedelic drugs. 
It may take 10 years to develop psilocybin as a licensed treatment for depression, but during this time, important knowledge will be acquired about how to maximise its potential. 
We will be keen to disseminate our findings. David Nutt and Val Curran have excellent relations with media and are frequently invited to give radio and television interviews, public lectures and scientific presentations. Importantly, there is a natural public and scientific interest in this subject matter which will greatly assist the process of dissemination, and ultimately maximise impact.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-05-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>508395</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>600000</gtr:amountPounds><gtr:country>Georgia</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Mosley Foundation</gtr:description><gtr:end>2019-01-02</gtr:end><gtr:fundingOrg>Mosley Foundation</gtr:fundingOrg><gtr:id>8FF44A21-AF24-492E-8500-E085BB30BC15</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A9880E21-2357-40EC-A411-6C569C9E4F44"><gtr:id>A9880E21-2357-40EC-A411-6C569C9E4F44</gtr:id><gtr:title>The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level-Dependent Resting State Functional Connectivity.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3844d2e4191ceba4697c082897237ad4"><gtr:id>3844d2e4191ceba4697c082897237ad4</gtr:id><gtr:otherNames>Carhart-Harris RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B324217E-61D1-42A8-9F3D-B062BC9067F6"><gtr:id>B324217E-61D1-42A8-9F3D-B062BC9067F6</gtr:id><gtr:title>Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse.</gtr:title><gtr:parentPublicationTitle>Pharmacological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8e3a1452a9992adec71fb56290a99966"><gtr:id>8e3a1452a9992adec71fb56290a99966</gtr:id><gtr:otherNames>Korpi ER</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0031-6997</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2A9F860D-7EE3-4B6D-AB1D-A157ACA046AD"><gtr:id>2A9F860D-7EE3-4B6D-AB1D-A157ACA046AD</gtr:id><gtr:title>Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3844d2e4191ceba4697c082897237ad4"><gtr:id>3844d2e4191ceba4697c082897237ad4</gtr:id><gtr:otherNames>Carhart-Harris RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A649F5B1-BF72-4A97-9B00-F7ED5A7D130D"><gtr:id>A649F5B1-BF72-4A97-9B00-F7ED5A7D130D</gtr:id><gtr:title>Broadband cortical desynchronization underlies the human psychedelic state.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/173372c773cb74de920a320f6973eae7"><gtr:id>173372c773cb74de920a320f6973eae7</gtr:id><gtr:otherNames>Muthukumaraswamy SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/23D0DA5D-1F26-4690-9DEA-5BE9EFD0CE87"><gtr:id>23D0DA5D-1F26-4690-9DEA-5BE9EFD0CE87</gtr:id><gtr:title>Psychiatry's next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3844d2e4191ceba4697c082897237ad4"><gtr:id>3844d2e4191ceba4697c082897237ad4</gtr:id><gtr:otherNames>Carhart-Harris RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C7E1A45E-44C6-4CEF-BAD3-8FACB63F2DB6"><gtr:id>C7E1A45E-44C6-4CEF-BAD3-8FACB63F2DB6</gtr:id><gtr:title>Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.</gtr:title><gtr:parentPublicationTitle>The lancet. Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3844d2e4191ceba4697c082897237ad4"><gtr:id>3844d2e4191ceba4697c082897237ad4</gtr:id><gtr:otherNames>Carhart-Harris RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2215-0366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5B6A3335-328D-4F83-B668-91D7A6FDF992"><gtr:id>5B6A3335-328D-4F83-B668-91D7A6FDF992</gtr:id><gtr:title>Effects of Schedule I drug laws on neuroscience research and treatment innovation.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5ebc5f1341b86df7fd71794875b2749b"><gtr:id>5ebc5f1341b86df7fd71794875b2749b</gtr:id><gtr:otherNames>Nutt DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-003X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2FCB9E24-CDF9-4D92-AFE1-22CC66EFF272"><gtr:id>2FCB9E24-CDF9-4D92-AFE1-22CC66EFF272</gtr:id><gtr:title>Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3844d2e4191ceba4697c082897237ad4"><gtr:id>3844d2e4191ceba4697c082897237ad4</gtr:id><gtr:otherNames>Carhart-Harris RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8D9DC7BC-2983-45AB-A046-775842AEF08F"><gtr:id>8D9DC7BC-2983-45AB-A046-775842AEF08F</gtr:id><gtr:title>Enhanced repertoire of brain dynamical states during the psychedelic experience.</gtr:title><gtr:parentPublicationTitle>Human brain mapping</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d3db64ae20e1338c09b124f0eda10a8f"><gtr:id>d3db64ae20e1338c09b124f0eda10a8f</gtr:id><gtr:otherNames>Tagliazucchi E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1065-9471</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BE8512F8-F3F2-499F-B047-5CCA6EA2A8E5"><gtr:id>BE8512F8-F3F2-499F-B047-5CCA6EA2A8E5</gtr:id><gtr:title>Was it a vision or a waking dream?</gtr:title><gtr:parentPublicationTitle>Frontiers in psychology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6ed5c999f2205c249bed873aaf34c32f"><gtr:id>6ed5c999f2205c249bed873aaf34c32f</gtr:id><gtr:otherNames>Carhart-Harris R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1664-1078</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C95AD7D3-C72B-48A6-AE93-64E64F98CED1"><gtr:id>C95AD7D3-C72B-48A6-AE93-64E64F98CED1</gtr:id><gtr:title>Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis.</gtr:title><gtr:parentPublicationTitle>Schizophrenia bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3844d2e4191ceba4697c082897237ad4"><gtr:id>3844d2e4191ceba4697c082897237ad4</gtr:id><gtr:otherNames>Carhart-Harris RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0586-7614</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3CA0EEA8-7917-4A22-8BF0-4F9F101ADF36"><gtr:id>3CA0EEA8-7917-4A22-8BF0-4F9F101ADF36</gtr:id><gtr:title>LSD enhances suggestibility in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3844d2e4191ceba4697c082897237ad4"><gtr:id>3844d2e4191ceba4697c082897237ad4</gtr:id><gtr:otherNames>Carhart-Harris RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9ACFC259-AFA2-42F3-BC52-C51A6F2D90CA"><gtr:id>9ACFC259-AFA2-42F3-BC52-C51A6F2D90CA</gtr:id><gtr:title>Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/334c9136b2450fe695b3b016b3d6b265"><gtr:id>334c9136b2450fe695b3b016b3d6b265</gtr:id><gtr:otherNames>Nutt D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9CCE7C7E-6939-4B60-B6F0-C9FAD56C48DD"><gtr:id>9CCE7C7E-6939-4B60-B6F0-C9FAD56C48DD</gtr:id><gtr:title>A web-based survey on mephedrone.</gtr:title><gtr:parentPublicationTitle>Drug and alcohol dependence</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3844d2e4191ceba4697c082897237ad4"><gtr:id>3844d2e4191ceba4697c082897237ad4</gtr:id><gtr:otherNames>Carhart-Harris RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0376-8716</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/103AB56D-BBE0-4BAB-8D93-C8E0BEF652E4"><gtr:id>103AB56D-BBE0-4BAB-8D93-C8E0BEF652E4</gtr:id><gtr:title>The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories.</gtr:title><gtr:parentPublicationTitle>The international journal of neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3844d2e4191ceba4697c082897237ad4"><gtr:id>3844d2e4191ceba4697c082897237ad4</gtr:id><gtr:otherNames>Carhart-Harris RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1461-1457</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/199A0BA7-68BF-49AB-A6B1-28CEF7025E71"><gtr:id>199A0BA7-68BF-49AB-A6B1-28CEF7025E71</gtr:id><gtr:title>The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs.</gtr:title><gtr:parentPublicationTitle>Frontiers in human neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3844d2e4191ceba4697c082897237ad4"><gtr:id>3844d2e4191ceba4697c082897237ad4</gtr:id><gtr:otherNames>Carhart-Harris RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1662-5161</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J00460X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>